Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials

References

• Mobasseri M, Shirmohammadi M, Amiri T, et al. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98–115.
   PubMedGoogle Scholar
• Whicher CA, O’Neill S, Holt RIG. Diabetes in the UK: 2019. Diabet Med. 2020;37(2):242–247.
   PubMedGoogle Scholar
• Divers J, Mayer-Davis E, Lawrence JM, et al. Trends in incidence of type 1 and type 2 diabetes among youths - selected counties and indian Reservations, United States, 2002-2015. MMWR Morb Mortal Wkly Rep. 2020;69(6):161–165.
   PubMed Web of Science ®Google Scholar
• Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):7–19.
   PubMedGoogle Scholar
• Lawrence JM, Divers J, Isom S, et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA. 2021;326(8):717–727.
   PubMed Web of Science ®Google Scholar
• Leslie RD, Evans-Molina C, Freund-Brown J, et al. Adult-onset type 1 diabetes: current understanding and challenges. Diabetes Care. 2021;44(11):2449–2456.
   PubMedGoogle Scholar
• Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract. 2008;82(2):247–255.
   PubMedGoogle Scholar
• Bonifacio E, Ziegler AG. Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):513–525.
   PubMedGoogle Scholar
• Hyöty H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002;45(10):1353–1361.
   PubMed Web of Science ®Google Scholar
• Couper JJ, Haller MJ, Greenbaum CJ, et al. ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):20–27.
   PubMedGoogle Scholar
• Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974.
   PubMed Web of Science ®Google Scholar
• Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr. 2013;162(2):330–4.e1.
   PubMedGoogle Scholar
• Alonso GT, Coakley A, Pyle L, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes in colorado children, 2010-2017. Diabetes Care. 2020;43(1):117–121.
   PubMedGoogle Scholar
• Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399–1404.
   PubMed Web of Science ®Google Scholar
• DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449–2462.
   PubMed Web of Science ®Google Scholar
• Lind M, Svensson A-M, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–1982.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–486.
   PubMed Web of Science ®Google Scholar
• American Association of Diabetes, E. Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ. 2002;28(5):735–740.
   PubMedGoogle Scholar
• Orchard TJ, Nathan DM, Zinman B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. Jama. 2015;313(1):45–53.
   PubMed Web of Science ®Google Scholar
• Anderzén J, Hermann JM, Samuelsson U, et al. International benchmarking in type 1 diabetes: large difference in childhood HbA1c between eight high-income countries but similar rise during adolescence—A quality registry study. Pediatr Diabetes. 2020;21(4):621–627.
   PubMedGoogle Scholar
• NDA. Report 1: care Processes and Treatment Targets 2019-20, Full Report. [Cited 2021 Sep 02]. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2019—20.
   Google Scholar
• Gomes MB, Coral M, Cobas RA, et al. Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil. Diabetes Res Clin Pract. 2012;97(1):63–70.
   PubMed Web of Science ®Google Scholar
• Lepore G, Bruttomesso D, Nosari I, et al. Glycaemic control and microvascular complications in a large cohort of Italian Type 1 diabetic out-patients. Diabetes Nutr Metab. 2002;15(4):232–239.
   PubMedGoogle Scholar
• Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66–72.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010;39(3):641–654.
   PubMed Web of Science ®Google Scholar
• Hermanns N, Heinemann L, Freckmann G, et al. Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study. J Diabetes Sci Technol. 2019;13(4):636–644.
   PubMedGoogle Scholar
• Ferguson EC, Wright N, Regan F, et al. Variations in access to continuous glucose monitoring and flash glucose sensors for children and young people in England and Wales: a national survey. Arch Dis Child. 2020;105(6):609–610.
   PubMedGoogle Scholar
• Janes R, Titchener J, Pere J, et al. Understanding barriers to glycaemic control from the patient’s perspective. J Prim Health Care. 2013;5(2):114–122.
   PubMedGoogle Scholar
• Ahola AJ, Saraheimo M, Freese R, et al. Fear of hypoglycaemia and self-management in type 1 diabetes. J Clin Transl Endocrinol. 2016;4:13–18.
   PubMedGoogle Scholar
• The DCCT Research Group, Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988;11(7):567–573.
   PubMed Web of Science ®Google Scholar
• Snoek FJ. Barriers to good glycaemic control: the patient’s perspective. Int J Obesity. 2000;24(3):S12–S20.
   Google Scholar
• McGill JB, Ahmann A. Continuous Glucose Monitoring With Multiple Daily Insulin Treatment: Outcome Studies. Diabetes Technol Ther. 2017;19(S3(S3):S3–s12.
   Google Scholar
• Tricco AC, Ashoor MH, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. Bmj. 2014;349(oct01 6):g5459.
   PubMedGoogle Scholar
• Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–1497.
   PubMed Web of Science ®Google Scholar
• Iacobucci G. NHS England tells CCGs to end postcode lottery over diabetes glucose devices. BMJ. 2018;363:k4812.
   PubMedGoogle Scholar
• Lanning MS, Tanenbaum ML, Wong JJ, et al. Barriers to continuous glucose monitoring in people with type 1 diabetes: clinician perspectives. Diabetes Spectr. 2020;33(4):324–330.
   PubMedGoogle Scholar
• Bailey CJ, Barnett AH. Why is Exubera being withdrawn? BMJ. 2007;335(7630):1156.
   Google Scholar
• Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015;49(1):99–106.
   PubMedGoogle Scholar
• Gajewska KA, Bennett K, Biesma R, et al. Low uptake of continuous subcutaneous insulin infusion therapy in people with type 1 diabetes in Ireland: a retrospective cross-sectional study. BMC Endocr Disord. 2020;20(1):92.
   PubMedGoogle Scholar
• Hermann JM, Miller KM, Hofer SE, et al. The Transatlantic HbA 1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabetic Med. 2020;37(5):848–855.
   PubMed Web of Science ®Google Scholar
• NDA. National Diabetes Insulin Pump Audit: summary Report 2017-18. 2019 2021 Sep 02. https://www.diabetes.org.uk/resources-s3/2019-09/Insulin_%20Summary_2019_v3.pdf.
   Google Scholar
• Danne T, Phillip M, Buckingham BA, et al. ISPAD clinical practice consensus guidelines 2018: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):115–135.
   PubMedGoogle Scholar
• FDA, SYMLIN (pramlintide acetate) injection. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin.cfm. 2005.
   Google Scholar
• Weyer C, Maggs D, Young A, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7(14):1353–1373.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204–1212.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Frias JP, Edelman SV, et al. Pramlintide improved measures of glycemic control and body weight in patients with type I diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013;125(3):136–144.
   PubMed Web of Science ®Google Scholar
• Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864–876.
   PubMed Web of Science ®Google Scholar
• Groop P-H, Dandona P, Phillip M, et al. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(10):845–854.
   PubMed Web of Science ®Google Scholar
• EMA. First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. 2019 2021 Sep 01. https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes.
   Google Scholar
• Kemp, Adrian https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html#. 2019
   Google Scholar
• EMA. Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus. 2021 Nov 20. https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-forxiga-dapagliflozin-5mg-should-no-longer-be-used_en.pdf.
   Google Scholar
• Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017;377(24):2337–2348.
   PubMed Web of Science ®Google Scholar
• Kandaswamy R, et al. OPTN/SRTR 2016 Annual Data Report: pancreas. Am J Transplant. 2018;18(Suppl 1):114–171.
   PubMedGoogle Scholar
• Dean PG, Kukla A, Stegall MD, et al. Pancreas transplantation. Bmj. 2017;357:j1321.
   PubMedGoogle Scholar
• CITR. Collaborative Islet Transplant Registry: ninth Annual Report. https://citregistry.org/system/files/9AR_Report.pdf. 2016 03/09/2021].
   Google Scholar
• Potter KJ, Westwell-Roper CY, Klimek-Abercrombie AM, et al. Death and dysfunction of transplanted β-cells: lessons learned from type 2 diabetes? Diabetes. 2014;63(1):12–19.
   PubMedGoogle Scholar
• Rickels MR, Evans-Molina C, Bahnson HT, et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Investig. 2020;130(4):1850–1862.
   PubMedGoogle Scholar
• Madsbad S, Stock PG, Gustafson SK, et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979;2(6200):1257–1259.
   PubMedGoogle Scholar
• Skyler JS. Primary and secondary prevention of Type 1 diabetes. Diabet Med. 2013;30(2):161–169.
   PubMedGoogle Scholar
• Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–1330.
   PubMed Web of Science ®Google Scholar
• Vickery BP, Scurlock AM, Jones SM, et al. Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol. 2011;127(3):576–584.
   PubMed Web of Science ®Google Scholar
• Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 2010;59(9):2087–2093.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial--Type 1 Diabetes Study Group, Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685–1691.
   PubMedGoogle Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care. 2005;28(5):1068–1076.
   PubMed Web of Science ®Google Scholar
• Vandemeulebroucke E, Gorus FK, Decochez K, et al. Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab. 2009;35(4):319–327.
   PubMedGoogle Scholar
• Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746–1755.
   PubMed Web of Science ®Google Scholar
• Elding Larsson H, Lundgren M, Jonsdottir B, et al. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes. 2018;19(3):410–419.
   PubMedGoogle Scholar
• Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016;8(8):889–906.
   PubMed Web of Science ®Google Scholar
• Hagopian W, Ferry RJ, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901–3908.
   PubMed Web of Science ®Google Scholar
• Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487–497.
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56(2):391–400.
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. N Engl J Med. 2005;352(25):2598–2608.
   PubMed Web of Science ®Google Scholar
• Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–613.
   PubMed Web of Science ®Google Scholar
• Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021; 13(583):506–510.
   Google Scholar
• Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals. 2021 Oct 14. https://investors.proventionbio.com/2021-07-06-Provention-Bio-Receives-Complete-Response-Letter-CRL-to-Biologics-License-Application-BLA-for-Teplizumab-for-the-Delay-of-Clinical-Type-1-Diabetes-T1D-in-At-risk-Individuals.
   Google Scholar
• ClincalTrial.gov. Recent-onset type 1 diabetes trial evaluating efficacy and safety of teplizumab (PROTECT). https://clinicaltrials.gov/ct2/show/NCT03875729. 2019 14/10/2021].
   Google Scholar
• FDA. FDA approves first drug that can delay onset of type 1 diabetes. 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes. Cited 2023 Feb 14.
   Google Scholar
• Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol. 2003;3(2):123–132.
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53(4):614–623.
   PubMed Web of Science ®Google Scholar
• Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746–2754.
   PubMed Web of Science ®Google Scholar
• Ambery P, Donner TW, Biswas N, et al. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med. 2014;31(4):399–402.
   PubMed Web of Science ®Google Scholar
• BNF. Rituximab. 2021 Oct 14. https://bnf.nice.org.uk/drug/rituximab.html.
   Google Scholar
• Pescovitz MD. Rituximab, an Anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5p1):859–866.
   PubMedGoogle Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–2152.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640–2653.
   PubMed Web of Science ®Google Scholar
• Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008;105(48):18895–18900.
   PubMed Web of Science ®Google Scholar
• Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(8):502–514.
   PubMedGoogle Scholar
• Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103(9):1243–1252.
   PubMed Web of Science ®Google Scholar
• BNF. Abatacept. 2021 Oct 14. https://bnf.nice.org.uk/drug/abatacept.html.
   Google Scholar
• Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with Abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–419.
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1. 2013 [ Cited 2022 Oct 07.
   Google Scholar
• Liu CM, McKenna JK, Krueger GG. Alefacept: a novel biologic in the treatment of psoriasis. Drugs Today (Barc). 2004;40(12):961–974.
   PubMedGoogle Scholar
• Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285–3296.
   PubMed Web of Science ®Google Scholar
• Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med. 2020;383(21):2007–2017.
   PubMed Web of Science ®Google Scholar
• Citro A, Valle A, Cantarelli E, et al. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes. 2014;64(4):1329–1340.
   PubMedGoogle Scholar
• Piemonti L, Keymeulen B, Gillard P, et al. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2022;24(9):1840–1849.
   PubMedGoogle Scholar
• Maffi P, Lundgren T, Tufveson G, et al. Targeting CXCR1/2 does not improve insulin secretion after pancreatic islet transplantation: a phase 3, double-blind, randomized, placebo-controlled trial in type 1 diabetes. Diabetes Care. 2020;43(4):710–718.
   PubMedGoogle Scholar
• Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol. 2014;154(1):84–89.
   PubMedGoogle Scholar
• Gregory JW, Carter K, Cheung WY, et al. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open. 2021;11(10):e049595.
   PubMedGoogle Scholar
• ClinicalTrial.gov. Clinical phase II/III trial of ustekinumab to treat type 1 diabetes (UST1D2). https://clinicaltrials.gov/ct2/show/NCT03941132. 2019 2021 Oct 15.
   Google Scholar
• Ludvigsson J. Combination therapy for preservation of beta cell function in Type 1 diabetes: new attitudes and strategies are needed! Immunol Lett. 2014;159(1–2):30–35.
   PubMed Web of Science ®Google Scholar
• Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):306–316.
   PubMed Web of Science ®Google Scholar
• Parker MJ, Xue S, Alexander JJ, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes. 2009;58(10):2277–2284.
   PubMedGoogle Scholar
• Haller MJ, Schatz DA, Skyler JS, et al. Low-dose anti-thymocyte globulin (ATG) preserves β-cell function and improves HbA(1c) in new-onset type 1 diabetes. Diabetes Care. 2018;41(9):1917–1925.
   PubMed Web of Science ®Google Scholar
• Haller MJ, Long SA, Blanchfield JL, et al. Low-dose anti-thymocyte globulin preserves c-peptide, reduces HbA(1c), and increases regulatory to conventional t-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes. 2019;68(6):1267–1276.
   PubMedGoogle Scholar
• Lin A, Mack JA, Bruggeman B, et al. Low-Dose ATG/GCSF in established type 1 diabetes: a five-year follow-up report. Diabetes. 2021;70(5):1123–1129.
   PubMedGoogle Scholar
• Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–5158.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157.
   PubMed Web of Science ®Google Scholar
• Sarkar G, Alattar M, Brown RJ, et al. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care. 2014;37(3):666–670.
   PubMed Web of Science ®Google Scholar
• ClincalTrial.gov. A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes. https://clinicaltrials.gov/ct2/show/results/NCT01928329. 2013 15/10/20201].
   Google Scholar
• Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221–232.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016;39(10):1702–1710.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693–1701.
   PubMed Web of Science ®Google Scholar
• Pozzilli P, Bosi E, Cirkel D, et al. Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2020;105(6) e2192–e2206 .
   Google Scholar
• von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021;9(4):212–224.
   PubMedGoogle Scholar
• Hari Kumar KVS, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–e58.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009;52(8):1680–1682.
   PubMedGoogle Scholar
• Griffin KJ, Thompson PA, Gottschalk M, et al. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014;2(9):710–718.
   PubMed Web of Science ®Google Scholar
• Yin T, Kuo S-C, Chang -Y-Y, et al. Verapamil use is associated with reduction of newly diagnosed diabetes mellitus. J Clin Endocrinol Metab. 2017;102(7):2604–2610.
   PubMedGoogle Scholar
• Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med. 2018;24(8):1108–1112.
   PubMedGoogle Scholar
• ClinicalTrial.gov. Verapamil SR in Adults With Type 1 Diabetes (Ver-A-T1D). 2020 2021 Oct 15. https://www.clinicaltrials.gov/ct2/show/NCT04545151.
   Google Scholar
• Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–2116.
   PubMed Web of Science ®Google Scholar
• Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine u100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;(44):dc202877.
   Google Scholar
• Kazda CM, Chien J, Zhang Q, et al. 192-OR: glycemic control with once-weekly basal insulin fc (BIF) in persons with type 2 diabetes mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a phase 2 study. Diabetes. 2021;70(Supplement 1):192–OR.
   Google Scholar
• Eldor R, Arbit E, Corcos A, et al. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One. 2013;8(4):e59524.
   PubMed Web of Science ®Google Scholar
• Eldor R, Neutel J, Homer K, et al. Efficacy and safety of 28-day treatment with oral insulin (ORMD −0801) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2021;23(11):2529–2538.
   PubMedGoogle Scholar
• ClinicalTrial.gov. A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus. 2018 2021 Nov 16. https://clinicaltrials.gov/ct2/show/results/NCT03467932.
   Google Scholar
• ClincalTrial.gov. Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. 2020 2021 Oct 15. https://clinicaltrials.gov/ct2/show/NCT04606576.
   Google Scholar
• ClinicalTrial.gov. A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. 2021 Oct 15. https://clinicaltrials.gov/ct2/show/NCT04754334
   Google Scholar
• El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017;389(10067):369–380.
   PubMed Web of Science ®Google Scholar
• 2021 Nov 21. https://www.jdrf.org/blog/2019/12/23/fda-grants-breakthrough-device-status-ilet-bionic-pancreas/.
   Google Scholar
• ClincalTrial.gov. The insulin-only bionic pancreas pivotal trial. https://clinicaltrials.gov/ct2/show/NCT04200313. 2019 2021 Nov 24.
   Google Scholar
• Messer LH, Buckingham BA, Cogen F, et al. Positive Impact of the Bionic Pancreas on diabetes control in youth 6-17 years old with type 1 diabetes: a multicenter randomized trial. Diabetes Technol Ther. 2022;24(10):712–725.
   PubMedGoogle Scholar
• Kruger D, Kass A, Lonier J, et al. A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther. 2022;24(10):697–711.
   PubMedGoogle Scholar
• Robert T, De Mesmaeker I, Stangé GM, et al. Functional beta cell mass from device-encapsulated hESC-derived pancreatic endoderm achieving metabolic control. Stem Cell Reports. 2018;10(3):739–750.
   PubMed Web of Science ®Google Scholar
• Millman JR, Xie C, Van Dervort A, et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nat Commun. 2016;7(1):11463.
   PubMedGoogle Scholar
• HENRY RR, Pettus J, Wilensky J, et al. Initial clinical evaluation of VC-01TM combination product—a stem cell–derived islet replacement for type 1 diabetes (T1D). Diabetes. 2018;67(Supplement 1):138–OR.
   Google Scholar
• Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4):246–251.
   PubMedGoogle Scholar
• Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7(2):101–107.
   PubMed Web of Science ®Google Scholar